Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Solid Tumors

NCT ID: NCT02721043


Title
Phase I, Open Label, Study Of Pgv001 A Multi-Peptide Therapeutic Vaccine Platform For Use In The Treatment Of Solid Tumors In The Adjuvant Setting
Purpose
The purpose of this study is to test the safety, tolerability, and immunogenicity of Personalized Genomic Vaccine 001 (PGV001) in subjects with advanced non-hematologic malignancies. PGV001 is a peptide vaccine that is based on a patient's own tumor sequence. Each patient's tumor is sequenced and peptides that correspond to the tumors are made. These peptides combined with the adjuvant Poly-ICLC (Hiltonol®, Oncovir) make PGV001. The adjuvant Poly-ICLC is added to boost the immune response to the peptides and together will expand immune cells to target cancer.
Details
Conditions
Solid Tumors
Keywords
Personalized vaccine, Poly-ICLC, Immunotherapy, Cancer
Source
Icahn School of Medicine at Mount Sinai
Sponsors
Nina Bhardwaj
Status
Recruiting
Acronym
Last Updated
22 May 2016
URL
Official Link
Locations
United States